Context: https://seekingalpha.com/article/4867238-generate-biomedicines-begins-ipo-push-with-major-collaboration-deals

Resolution Criteria

Generate Biomedicines filed for a Nasdaq IPO on February 4, 2026 under the proposed ticker GENB. The market resolves YES if GENB begins trading on Nasdaq before 5pm EST on March 31, 2026. Resolution can be verified via Nasdaq's official listing page or financial news sources reporting the IPO completion date and time. The market resolves NO if the IPO has not commenced trading by the deadline.

Background

Generate Biomedicines is a clinical-stage biotech that uses generative AI and scalable biohardware to design protein therapeutics across modalities. The company's lead program, GB-0895, is a long-acting anti-TSLP monoclonal antibody in Phase 3 for severe asthma and in Phase 1b for COPD, with the first Phase 3 patient dosed January 26, 2026. Lead underwriters include Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor.

Considerations

Biotech IPO timelines are subject to market conditions and regulatory approval. Recent biotech IPOs in early 2026—Eikon Therapeutics, Veradermics, and Aktis Oncology—all raised more than $250 million, indicating favorable market conditions for the sector. However, pricing and exact IPO date have not yet been disclosed, and delays are possible.

This description was generated by AI.